News

July 18, 2018July 18, 2018

Phase 1 Trial of Investigational BT-11 Begins Dosing First Volunteers, Landos Announces

News

A Phase 1 clinical trial testing Landos Biopharma’s investigational therapy BT-11 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), has begun dosing healthy volunteers. Landos plans to ... Read more

July 16, 2018July 16, 2018

Young IBD Patients at High Risk of Developing Anxiety, Depression, Researchers Say

News

Young people with inflammatory bowel disease (IBD) — especially women and those with active disease — are at greater risk of developing anxiety and depression, a Dutch study shows. These ... Read more

July 13, 2018July 13, 2018

Genetic Changes Specific to IBD-associated Colorectal Cancer May Help Identify High-risk Patients

News

Newly discovered genetic alterations that precede the development of colorectal cancer associated with inflammatory bowel disease (IBD) may help in the development of diagnostic tools to identify patients at the ... Read more

July 11, 2018July 11, 2018

Crohn’s & Colitis Foundation Awards Funding to Vedanta for New Microbiome-Derived Therapeutic Program

News

The Crohn’s & Colitis Foundation has granted Vedanta Biosciences funding for its new microbiome-derived therapeutic program for the treatment of inflammatory bowel disease (IBD). This program aims to develop therapeutics ... Read more

July 9, 2018July 9, 2018

Innovate Partnering with University of Maryland to Investigate Larazotide’s Potential to Treat IBD

News

Innovate Biopharmaceuticals Inc. will collaborate with a researcher at the University of Maryland School of Medicine to develop larazotide as a potential treatment for diseases that affect the intestinal barrier, ... Read more

July 6, 2018July 6, 2018

Finalists Announced for UnitedHealth and Lyfebulb’s IBD-related Innovation Challenge

News

Lyfebulb and UnitedHealth Group have selected the 11 finalists for their innovation challenge, which will reward the most innovative solutions to help patients with inflammatory bowel disease (IBD). These contestants will ... Read more

July 2, 2018July 2, 2018

Byproduct of Cholesterol Metabolism May Activate Gut Immune Cells to Cause IBD, Study Says

News

A cholesterol metabolite — a byproduct of cholesterol metabolism — triggers an abnormal immune response in inflammatory bowel disease (IBD) further aggravating such diseases, researchers found in a mouse study. ... Read more

June 29, 2018June 29, 2018

Compound Used in Food Packaging Linked to Severe IBD Symptoms in Animal Study

News

Bisphenol-A, a compound used in the production of some plastics and resins that line containers of canned foods and beverages, was seen to worsen symptoms and increased mortality in a ... Read more

June 27, 2018June 27, 2018

Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio

News

Aerpio Pharmaceuticals announced a licensing agreement with Gossamer Bio to develop and commercialize Aerpio’s investigative therapy AKB-4924 as a treatment for inflammatory bowel disease (IBD). AKB-4924 (to be changed to GB004) is a hypoxia-inducible factor-1 alpha ... Read more

June 25, 2018June 25, 2018

International GEM Project Studying Crohn’s Disease Reaches Goal of 5,000 Participants

News

The Genetic, Environmental, Microbial (GEM) Project — the world’s largest clinical study investigating the causes of Crohn’s disease — has reached its goal of recruiting 5,000 participants, Crohn’s and Colitis Canada recently announced. ... Read more